Pacific Biosciences Of California (PACB) Cash from Operations (2010 - 2026)

Pacific Biosciences Of California has reported Cash from Operations for 17 years, with the latest figure at -$35.6 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 21.13% year-over-year to -$35.6 million in Q2 2026; TTM through Jun 2026 was -$118.0 million, a 21.06% increase from a year earlier, with the FY2025 full-year figure at -$111.2 million, up 46.03% from the prior year.
• Cash from Operations was -$35.6 million for Q2 2026 at Pacific Biosciences Of California, up from -$44.7 million in the prior quarter.
• The five-year high for Cash from Operations was -$18.7 million in Q3 2025, with the low at -$94.7 million in Q1 2023.
• Average Cash from Operations over 5 years is -$51.1 million, with a median of -$49.9 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 285.46% in 2022, then surged 58.85% in 2025.
• Over 5 years, Cash from Operations stood at -$60.6 million in 2022, then increased by 4.96% to -$57.6 million in 2023, then surged by 46.75% to -$30.6 million in 2024, then surged by 37.78% to -$19.1 million in 2025, then tumbled by 86.6% to -$35.6 million in 2026.
• The last three Cash from Operations figures came in at -$35.6 million (Q2 2026), -$44.7 million (Q1 2026), and -$19.1 million (Q4 2025), per Business Quant data.